trending Market Intelligence /marketintelligence/en/news-insights/trending/eukhjf64qqv4vb-pxssucg2 content esgSubNav
In This List

Orthofix gets US FDA approval for foot bone implant

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Orthofix gets US FDA approval for foot bone implant

Orthofix International NV said the U.S. Food and Drug Administration granted 510(k) clearance to its G-Beam fusion beaming system to treat Charcot foot, a condition where the bones in the foot weaken and collapse.

The Lewisville, Texas-based device-maker said the G-Beam devices can be implanted in the medial and lateral columns of the foot to provide alignment, stabilization and fixation.